Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction

MeSH terms

• ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors
• ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
• Antifungal Agents / administration & dosage*
• Antifungal Agents / adverse effects*
• Antifungal Agents / blood
• Antifungal Agents / pharmacokinetics
• Biological Availability
• Cytochrome P-450 CYP3A / metabolism
• Cytochrome P-450 CYP3A Inhibitors
• Drug Interactions
• Drug Monitoring
• Humans
• Immunosuppressive Agents / administration & dosage*
• Immunosuppressive Agents / adverse effects*
• Immunosuppressive Agents / blood
• Immunosuppressive Agents / pharmacokinetics
• Liver Transplantation / immunology
• Male
• Middle Aged
• Pulmonary Aspergillosis / drug therapy
• Pulmonary Aspergillosis / microbiology
• Pyrimidines / administration & dosage*
• Pyrimidines / adverse effects*
• Pyrimidines / blood
• Pyrimidines / pharmacokinetics
• Tacrolimus / administration & dosage*
• Tacrolimus / adverse effects*
• Tacrolimus / blood
• Tacrolimus / pharmacokinetics
• Triazoles / administration & dosage*
• Triazoles / adverse effects*
• Triazoles / blood
• Triazoles / pharmacokinetics
• Voriconazole